WO1994004541A2 - Protein kinase inhibitors and related compounds combined with taxol - Google Patents
Protein kinase inhibitors and related compounds combined with taxol Download PDFInfo
- Publication number
- WO1994004541A2 WO1994004541A2 PCT/US1993/007054 US9307054W WO9404541A2 WO 1994004541 A2 WO1994004541 A2 WO 1994004541A2 US 9307054 W US9307054 W US 9307054W WO 9404541 A2 WO9404541 A2 WO 9404541A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- tumors
- taxol
- compounds
- Prior art date
Links
- 0 B[C@](CC1(*)*C)([n]2c3c(C(C(N(CC)C4)O)=C4Cc4ccccc44)c5c2cccc5)OC1(*)N4C3=C Chemical compound B[C@](CC1(*)*C)([n]2c3c(C(C(N(CC)C4)O)=C4Cc4ccccc44)c5c2cccc5)OC1(*)N4C3=C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93918422A EP0655066A1 (en) | 1992-08-12 | 1993-07-30 | Protein kinase inhibitors and related compounds combined with taxol |
JP6506283A JPH08500112A (en) | 1992-08-12 | 1993-07-30 | Protein kinase inhibitors and related compounds in combination with taxol |
AU47876/93A AU4787693A (en) | 1992-08-12 | 1993-07-30 | Protein kinase inhibitors and related compounds combined with taxol |
KR1019950700489A KR950702994A (en) | 1992-08-12 | 1993-07-30 | PROTEIN KINASE INHIBITORS AND RELATED COMPOUNDS COMBINED WITH TAXOL |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92919992A | 1992-08-12 | 1992-08-12 | |
US07/929,199 | 1992-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994004541A2 true WO1994004541A2 (en) | 1994-03-03 |
WO1994004541A3 WO1994004541A3 (en) | 1994-06-09 |
Family
ID=25457472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/007054 WO1994004541A2 (en) | 1992-08-12 | 1993-07-30 | Protein kinase inhibitors and related compounds combined with taxol |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0655066A1 (en) |
JP (1) | JPH08500112A (en) |
KR (1) | KR950702994A (en) |
AU (1) | AU4787693A (en) |
CA (1) | CA2140653A1 (en) |
WO (1) | WO1994004541A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997001344A2 (en) * | 1995-06-27 | 1997-01-16 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
WO1997005140A1 (en) * | 1995-07-31 | 1997-02-13 | Novartis Ag | Trindene compounds |
WO1998032440A1 (en) * | 1997-01-28 | 1998-07-30 | The Procter & Gamble Company | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator |
WO1999047522A1 (en) * | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Granulatimide derivatives for use in cancer treatment |
WO2000001699A1 (en) * | 1998-07-02 | 2000-01-13 | Bayer Aktiengesellschaft | Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
WO2001000627A1 (en) * | 1999-06-28 | 2001-01-04 | Instituto Biomar S.A. | New indolocarbazole alkaloids from a marine actinomycete |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6274576B1 (en) | 1995-06-27 | 2001-08-14 | The Henry Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
US6291447B1 (en) | 1998-03-13 | 2001-09-18 | The University Of British Columbia | Granulatimide compounds and uses thereof |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6407131B1 (en) | 1997-05-16 | 2002-06-18 | The Procter & Gamble Company | Compounds and method for use thereof in the treatment of cancer or viral infections |
US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
WO2002064214A2 (en) * | 2001-02-09 | 2002-08-22 | F. Hoffmann-La Roche Ag | Anti cancer combination of substituted pyrroles and paclitaxel |
WO2002080937A1 (en) * | 2001-04-04 | 2002-10-17 | Cephalon, Inc. | Antineoplastic compositions comprising trk tyrosine kinase inhibitors and nucleotide analogs |
US6472385B1 (en) * | 1999-08-09 | 2002-10-29 | Trustees Of Darmouth College | Compositions and methods to enhance cancer chemotherapy in p53 defective tumors |
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6608096B1 (en) | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
WO2003092719A3 (en) * | 2002-04-29 | 2004-03-18 | Yissum Res Dev Co | Methods and compositions for modulating beta-catenin phosphorylation |
WO2004026319A2 (en) * | 2002-09-17 | 2004-04-01 | Centre National De La Recherche Scientifique | Pharmaceutical compositions increasing camp useful for the treatment of cancers |
EP1653972A1 (en) * | 2003-07-23 | 2006-05-10 | Creabilis Therapeutics s.r.l. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
US7371780B2 (en) | 2003-11-11 | 2008-05-13 | Amadeo Parissenti | Use of calphostin C to treat drug-resistant tumor cells |
US7820718B1 (en) * | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235776B1 (en) * | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
KR20080046161A (en) * | 2005-08-09 | 2008-05-26 | 요하네스 구텐베르크-유니버시타트 마인츠 | Staurosporine derivatives for treating non-small cell lung cancer |
CA2922575C (en) * | 2013-11-01 | 2022-10-11 | Newsouth Innovations Pty Limited | Pharmaceutical combinations for the treatment of cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155284A (en) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | Physiologically active substance k-252 derivative |
JPS63295589A (en) * | 1987-01-22 | 1988-12-01 | Kyowa Hakko Kogyo Co Ltd | Derivative of physiologically active substance k-252 |
EP0303697A1 (en) * | 1987-03-09 | 1989-02-22 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
EP0323171A2 (en) * | 1987-12-24 | 1989-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them |
-
1993
- 1993-07-30 KR KR1019950700489A patent/KR950702994A/en not_active Application Discontinuation
- 1993-07-30 EP EP93918422A patent/EP0655066A1/en not_active Withdrawn
- 1993-07-30 CA CA002140653A patent/CA2140653A1/en not_active Abandoned
- 1993-07-30 JP JP6506283A patent/JPH08500112A/en active Pending
- 1993-07-30 WO PCT/US1993/007054 patent/WO1994004541A2/en not_active Application Discontinuation
- 1993-07-30 AU AU47876/93A patent/AU4787693A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155284A (en) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | Physiologically active substance k-252 derivative |
JPS63295589A (en) * | 1987-01-22 | 1988-12-01 | Kyowa Hakko Kogyo Co Ltd | Derivative of physiologically active substance k-252 |
EP0303697A1 (en) * | 1987-03-09 | 1989-02-22 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
EP0323171A2 (en) * | 1987-12-24 | 1989-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, vol. 103, no. 21, 25 November 1985, Columbus, Ohio, US; abstract no. 171551e, T. TSURUO ET AL 'Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns' page 29 ; & CANCER CHEMOTHER. PHARMACOL., vol.15, no.1, 1985 pages 16 - 19 * |
CHEMICAL ABSTRACTS, vol. 107, no. 25, 21 December 1987, Columbus, Ohio, US; abstract no. 236750y, T. HIRATA ET AL 'Preparation of k-252 derivatives as protein kinase C inhibitors and drugs' page 796 ; cited in the application & JP,A,62 155 284 (KYOWA HAKKO KOGYO CO) 10 July 1987 * |
CHEMICAL ABSTRACTS, vol. 111, no. 21, 20 November 1989, Columbus, Ohio, US; abstract no. 194456g, T. HIRATA ET AL 'Preparation of K-252 derivatives as protein kinase C inhibitors and formulations containing them' page 743 ; cited in the application & JP,A,63 295 589 (KYOWA HAKKO HOGYO CO) 1 December 1988 * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol.85, no.2, January 1988, WASHINGTON US pages 582 - 586 R. L. FINE ET AL 'Phorbol esters induce multidrug resistance in human breast cancer cells' * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362207B1 (en) | 1995-04-12 | 2002-03-26 | The Procter & Gamble Company | Methods of treating viral infections with benzimidazoles |
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6552059B2 (en) | 1995-06-07 | 2003-04-22 | University Of Arizona Foundation | Pharmaceutical composition for and method of treating leukemia |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
WO1997001344A2 (en) * | 1995-06-27 | 1997-01-16 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
US6455593B1 (en) | 1995-06-27 | 2002-09-24 | The Henry Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
WO1997001344A3 (en) * | 1995-06-27 | 1997-03-27 | Jackson H M Found Military Med | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
US6274576B1 (en) | 1995-06-27 | 2001-08-14 | The Henry Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
WO1997005140A1 (en) * | 1995-07-31 | 1997-02-13 | Novartis Ag | Trindene compounds |
US6329355B1 (en) | 1997-01-28 | 2001-12-11 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US5900429A (en) * | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
WO1998032440A1 (en) * | 1997-01-28 | 1998-07-30 | The Procter & Gamble Company | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator |
US6271217B1 (en) | 1997-01-28 | 2001-08-07 | The Procter & Gamble Company | Method of treating cancer with a benzimidazole and a chemotherapeutic agent |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6482843B1 (en) | 1997-05-16 | 2002-11-19 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6864275B1 (en) | 1997-05-16 | 2005-03-08 | Uaf Technologies And Research, Llc | Compounds and methods for use thereof in the treatment of cancer |
US6710065B1 (en) | 1997-05-16 | 2004-03-23 | Uaf Technologies And Research, Llc | Compounds and methods for use thereof in the treatment of cancer |
US6407131B1 (en) | 1997-05-16 | 2002-06-18 | The Procter & Gamble Company | Compounds and method for use thereof in the treatment of cancer or viral infections |
US6420411B1 (en) | 1997-05-16 | 2002-07-16 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6900235B1 (en) | 1997-05-16 | 2005-05-31 | Uaf Technologies And Research, Llc | Benzimidazole compounds, and pharmaceutical compositions and unit dosages thereof |
US6423736B1 (en) | 1997-05-16 | 2002-07-23 | The Proctor & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6291447B1 (en) | 1998-03-13 | 2001-09-18 | The University Of British Columbia | Granulatimide compounds and uses thereof |
WO1999047522A1 (en) * | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Granulatimide derivatives for use in cancer treatment |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
WO2000001699A1 (en) * | 1998-07-02 | 2000-01-13 | Bayer Aktiengesellschaft | Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7820718B1 (en) * | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
WO2001000627A1 (en) * | 1999-06-28 | 2001-01-04 | Instituto Biomar S.A. | New indolocarbazole alkaloids from a marine actinomycete |
JP2003503412A (en) * | 1999-06-28 | 2003-01-28 | インスティトゥート・バイオマール・ソシエダード・アノニマ | Novel indolocarbazole alkaloids derived from marine actinomycetes |
US6852715B1 (en) | 1999-06-28 | 2005-02-08 | Instituto Biomar S.A. | Indolocarbazole alkaloids from a marine actinomycete |
AU775414B2 (en) * | 1999-06-28 | 2004-07-29 | Instituto Biomar S.A. | New indolocarbazole alkaloids from a marine actinomycete |
US6472385B1 (en) * | 1999-08-09 | 2002-10-29 | Trustees Of Darmouth College | Compositions and methods to enhance cancer chemotherapy in p53 defective tumors |
US6906091B2 (en) | 1999-08-13 | 2005-06-14 | Uaf Technologies And Research, Llc | Method of cancer treatment |
US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6720349B2 (en) | 2000-09-26 | 2004-04-13 | Uaf Technologies And Research, Llc | Compounds for use in the treatment of cancer or viral infections |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6608096B1 (en) | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
WO2002064214A2 (en) * | 2001-02-09 | 2002-08-22 | F. Hoffmann-La Roche Ag | Anti cancer combination of substituted pyrroles and paclitaxel |
WO2002064214A3 (en) * | 2001-02-09 | 2003-05-30 | Hoffmann La Roche | Anti cancer combination of substituted pyrroles and paclitaxel |
WO2002080937A1 (en) * | 2001-04-04 | 2002-10-17 | Cephalon, Inc. | Antineoplastic compositions comprising trk tyrosine kinase inhibitors and nucleotide analogs |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
WO2003092719A3 (en) * | 2002-04-29 | 2004-03-18 | Yissum Res Dev Co | Methods and compositions for modulating beta-catenin phosphorylation |
WO2004026319A2 (en) * | 2002-09-17 | 2004-04-01 | Centre National De La Recherche Scientifique | Pharmaceutical compositions increasing camp useful for the treatment of cancers |
WO2004026319A3 (en) * | 2002-09-17 | 2004-09-02 | Centre Nat Rech Scient | Pharmaceutical compositions increasing camp useful for the treatment of cancers |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
EP1653972A1 (en) * | 2003-07-23 | 2006-05-10 | Creabilis Therapeutics s.r.l. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
US7371780B2 (en) | 2003-11-11 | 2008-05-13 | Amadeo Parissenti | Use of calphostin C to treat drug-resistant tumor cells |
US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
US11332480B2 (en) | 2017-04-27 | 2022-05-17 | Pharma Mar, S.A. | Antitumoral compounds |
US11339180B2 (en) | 2017-04-27 | 2022-05-24 | Pharma Mar, S.A. | Antitumoral compounds |
US11713325B2 (en) | 2017-04-27 | 2023-08-01 | Pharma Mar, S.A. | Antitumoral compounds |
Also Published As
Publication number | Publication date |
---|---|
CA2140653A1 (en) | 1994-03-03 |
WO1994004541A3 (en) | 1994-06-09 |
EP0655066A1 (en) | 1995-05-31 |
KR950702994A (en) | 1995-08-23 |
AU4787693A (en) | 1994-03-15 |
JPH08500112A (en) | 1996-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994004541A2 (en) | Protein kinase inhibitors and related compounds combined with taxol | |
US4942184A (en) | Water soluble, antineoplastic derivatives of taxol | |
US5157049A (en) | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol | |
FI91764C (en) | Analogous process for the preparation of acyldoxy ribonucleoside derivatives | |
JP5087052B2 (en) | Improved therapeutic agent | |
KR20020082458A (en) | Taxane prodrugs | |
HU224918B1 (en) | Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them | |
CN112245591A (en) | Construction of chemotherapy drug-hypoxia activated prodrug integrated prodrug self-assembled nanoparticles | |
PL182204B1 (en) | Derivatives of colchicine and their tharapeutic application | |
US7820839B2 (en) | Taxoid-fatty acid conjugates and pharmaceutical compositions thereof | |
WO2017142269A1 (en) | Novel indole derivative and anti-cancer composition containing same | |
CN107513089B (en) | Novel cytidine derivative dimer and application thereof | |
MUNAKATA et al. | Some structure-activity relationships for bactobolin analogs in the treatment of mouse leukemia P388 | |
PL202957B1 (en) | C10 ester substituted taxanes as antitumor agents | |
WO2004063211A1 (en) | Carbohydrate derivatives of paclitaxel and docetaxel, method for producing same and use thereof | |
AU699442B2 (en) | Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound | |
CN109836356B (en) | Aryl methyl ether derivative and application thereof | |
US20050054716A1 (en) | Pharmaceutical compositions and methods of using taxane derivatives | |
RU2200157C2 (en) | Pyridinecarboxamidines, method of their synthesis and pharmaceutical composition based on thereof | |
ES2307253T3 (en) | WORTMANNINA ANALOGS AND PROCEDURES FOR THE SAME USE. | |
CN117427176A (en) | Drug conjugate and application thereof | |
US20070286906A1 (en) | Dihydrobenzoquinone compounds | |
CN115181154A (en) | Pyxinol amide derivative, preparation method thereof and application thereof in field of medicines | |
CN115974890A (en) | Lycorine derivative, preparation method thereof and application thereof in preparing antitumor drugs | |
JP2000510148A (en) | 7-O-methoxymethyl paclitaxel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993918422 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2140653 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1993918422 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993918422 Country of ref document: EP |